

Dale B. Schenk
Application No.: 09/585,817
Page 2

PATENT

REMARKS

Applicant thanks the Examiner for today's telephonic interview, in which the election of two amyloid components from claim 15 was discussed. Restriction Requirement set forth in paragraph 2 of the Office Action mailed September 21, 2001 required Applicant to elect only one amyloid component from claim 15.


Claim 15 has been amended to include the amyloid component PrP D178N. Support for the amendment may be found at page 18, first row of Table 2.

For the same reasons stated in the Response to the Restriction/Election of Species Requirement filed February 21, 2002, Applicant traverses the Restriction Requirement set forth in paragraph 2 of the Office Action mailed September 21, 2001. Applicant provisionally elects the AScr and PrP D187N amyloid components of claim 15.

Applicant authorizes the Commissioner to charge any deficiency in fees associated with this paper or during the pendency of this application, or credit any overpayment, to Deposit Account No. 20-1430.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
RLC
PA 3203932 v1

Dale B. Schenk
Application No.: 09/585,817
Page 3

PATENT

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claim 15.

15. The method of claim 13, wherein said amyloid component is selected from the group consisting of AA, AL, ATTR, AapoA1, Alys, Agel, Acys, A β , AB₂M, AScr, PrP D178N, Acal, AIAPP and synuclein-NAC fragment.

PA 3203932 v1